Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life‐saving treatment
Open Access
- 9 October 2017
- journal article
- research article
- Published by Wiley in Clinical Case Reports
- Vol. 5 (12) , 1926-1930
Abstract
Key Clinical Message: Drug‐induced aHUS is rare; however, early diagnosis is vital to reduce morbidity and mortality. With confirmation of the diagnosis, eculizumab appears to be a viable treatment option to suppress the pro‐inflammatory surge. Furthermore, adverse side effects of medications such as carfilzomib and gemcitabine should be considered in the appropriate settings.Keywords
This publication has 17 references indexed in Scilit:
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2013
- Interactions between coagulation and complement—their role in inflammationSeminars in Immunopathology, 2011
- Atypical hemolytic uremic syndromeOrphanet Journal of Rare Diseases, 2011
- Chronic anemia resistant to erythropoietin in a patient treated with gemcitabine showing a hemolytic uremic syndrome (HUS)Gastroentérologie Clinique Et Biologique, 2010
- Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical PhenotypeClinical Journal of the American Society of Nephrology, 2010
- Gemcitabine-induced thrombotic microangiopathy: a systematic reviewNephrology Dialysis Transplantation, 2006
- A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disordersKidney International, 2006
- Syndrome hémolytique et urémique secondaire à la gemcitabine : à propos de six observations et revue de la littératureLa Revue de Médecine Interne, 2005
- Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpuraKidney International, 2001
- Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreasInvestigational New Drugs, 1994